Catalyst Countdown: Small-Caps on the Rise (BIVI, GFAI, MGRM, FRGT, REVB)

Each week, we explore a wave of near-term catalysts, searching for the next small-cap star ready to break out. We highlight five promising small-cap companies, zeroing in on key signals like resistance breakouts, unusual volume spikes, and consolidation trends without chasing bottoms.

BioVie Inc. (NASDAQ: BIVI) - BioVie Inc.'s shares closed last week's trading session up 37%, reaching $3.25. This month, the company announced its alignment with the U.S. Food and Drug Administration (FDA) for its upcoming SUNRISE-PD trial in Parkinson's disease (PD). As a result, BioVie is now in the trial start-up phase and aims to begin patient screening in Q4 2024. "The SUNRISE-PD trial targets the second of our two main objectives in developing bezisterim for Parkinson's, which is to improve patients' motor experiences in daily living," said Cuong Do, BioVie's President and CEO. "Our Phase 2a trial showed that bezisterim, combined with levodopa, could significantly improve motor control for patients with moderate to severe Parkinson's. The Phase 2 SUNRISE-PD trial will evaluate bezisterim’s effect on newly diagnosed patients, potentially broadening its applicability across all stages of the disease. Together, these trials could form the basis for a future study on disease progression, the ultimate goal of our PD program. Weare actively preparing for the trial and expect to begin patient screening by Q4 2024." Additionally, BioVie will present a poster at the 11th Aging Research and Drug Discovery Meeting (ARDD 2024), taking place from August 26-30 in Copenhagen, Denmark. Titled "Bezisterim Effects on Biological Age, Alzheimer's Epigenetics, and Neurologic Assessments," the presentation will offer an overview of bezisterim’s clinical data, focusing on its impact on longevity and biological aging. Christopher L. Reading, BioVie's Senior Vice President of the Alzheimer’s Disease Program, will deliver the presentation on Tuesday, August 27, from 14:40 15:00 CEST. As we await further updates from the company, we will be watching for a resistance break at $3.45 and or support to hold between $2.95 and $2.85.

--

Guardforce AI Co., Ltd. (NASDAQ: GFAI) - Guardforce AI Co., Ltd. shares increased 2%, closing at $1.38 in last week's trading session. The company recently announced the expansion of its Artificial Intelligence of Things (AIoT) Robot Advertising business into the U.S. market, starting with the deployment of over 200 robots in New York. This milestone is a key step in Guardforce AI's strategy to grow its advertising business. Additionally, the company has completed the proof-of-concept for a decentralized spatial computing solution on its robots, expected to launch in late August. These solutions are anticipated to create new revenue streams for Guardforce AI. To boost customer engagement and visibility, the U.S.-deployed robots are strategically positioned in high-traffic locations, such as restaurant entrances, supermarkets, and hotels. This will help establish a strong advertising network, increasing the reach and impact of both local and national brands. All robots are connected to the Guardforce AI Intelligent Cloud Platform (ICP), providing advertisers with real-time access to campaign data. This allows them to optimize their strategies based on detailed exposure metrics, including the number of impressions in specific timeframes and locations. Lei (Olivia) Wang, Chairwoman and CEO of Guardforce AI, stated, "We’re excited to expand our AIoT Robot Advertising business into the U.S., and the market response has been very positive. Even more exciting is the upcoming launch of our decentralized spatial computing solution. As the demand for computing power grows alongside AI and robotics, this will increase the value of our robots and offer an additional revenue stream. Although it takes time to localize these solutions, we look forward to expanding them into other regions." As we await further updates from the company, we will be watching for a resistance break at $1.45 and support to hold at $1.30.

--

Monogram Technologies Inc. (NASDAQ: MGRM) - Monogram Technologies Inc. shares closed last week’s trading session up nearly 1%, at $2.82. This month, the company announced a strategic collaboration with Shalby Limited (NSE), a global multi-specialty hospital chain and one of India's leading orthopedic groups, to conduct a multicenter clinical trial demonstrating the safety and effectiveness of the mBȏs TKA System. Shalby is the largest orthopedic hospital chain worldwide, ranked #1 in arthroplasty by volume. The group employs over 4,000 people across 14 hospitals in 13 cities and has treated more than 3 million patients. Shalby accounts for roughly 15% of India’s organized arthroplasty market, which performs around 200,000 TKAs annually, with a 20% compound annual growth rate. Currently operating in 8 countries, Shalby has aggressive international expansion plans. In May 2021, Shalby acquired California-based Consensus Orthopedics, establishing a U.S. presence. “Shalby Advanced Technologies, Inc., aims to be a top 10 global player in orthopedics within the next decade,” said Dr. Vikram Shah, Chairman of Shalby. “We believe many markets worldwide are underserved and recognize the critical role of advanced technologies in achieving our ambitious goals.” Additionally, during a Q2 2024 update call, Monogram announced it had successfully submitted its 510(k) application to the FDA for the mBȏs TKA System on July 19th. The application has passed administrative review and is now in the primary substantial review phase, expected to last approximately 60 days. The company anticipates an update from the FDA around September 17th. As we await further developments, we’ll be monitoring for increased trading volume, a resistance break at $2.95, and or continued support around $2.60.

--

Freight Technologies, Inc. (NASDAQ: FRGT) - Freight Technologies, Inc. shares closed last week’s trading session up 6% at $0.20. This month, the company announced its integration with Tecnomotum, one of Mexico’s largest data transmission companies for haulage. Tecnomotum provides customers with technology that enhances security, reduces accident risks, and optimizes fleet connectivity and logistics operations. The integration is expected to maximize savings, improve user experience, deliver real-time data, and streamline logistics processes. Javier Selgas, CEO of Fr8Tech, commented, "We are proud to offer our customers an even more seamless experience. Fr8App's dedication to partnering with key players in the logistics industry is unmatched. Each new integration reinforces our position as the most connected and integrable platform for cross-border shipping in the USMCAregion. By continuing to collaborate with industry leaders, Fr8App is at the forefront of simplifying logistics processes and improving visibility for our customers. Our focus on integration highlights our commitment to delivering the best possible service, showcasing our success in the logistics industry." Additionally, the company announced a partnership with IGNITION Investor Relations, a New Jersey-based firm, as part of its strategy to enhance Fr8Tech’s visibility with institutional and retail investors. "We’re excited about partnering with Ignition as our IR representative," said Donald Quinby, CFO of Fr8Tech. "With so much to communicate to the investment community, we’re thrilled to have the professionalism and expertise of the Ignition team. Their relevant IR experience and strong investment community network will complement our leadership as we work to share Fr8Tech’s value with investors." As we await further updates from the company, we will be watching for a resistance break at $0.22.

--

Revelation Biosciences, Inc. (NASDAQ: REVB) - Revelation Biosciences, Inc. shares ended last week’s trading session down nearly 4%, closing at $0.86. In a recent press release, the company announced the completion of dosing in its first-in-human Phase 1 clinical study of Gemini. The company also reported positive Phase 1 results, with the trial meeting its primary safety endpoint and showing statistically significant biomarker activity. “The Revelation team worked hard in the first half of 2024 to lay the groundwork for the successful advancement of Gemini, and we’re excited to report that the primary endpoint—evaluating safety and tolerability of escalating doses—was met. We identified the maximum tolerated dose in healthy volunteers and observed statistically significant dose-dependent upregulation of key biomarkers, demonstrating Gemini’s immunostimulatory preconditioning effect,” said James Rolke, CEO of Revelation. “In the second half of 2024, we look forward to building on this momentum with the launch of a Phase 1b study in CKD patients.” As we await further updates, we’ll be watching for consolidation at certain levels, given the company's recent breaks in support, or a potential resistance break at $0.96 with increased volume.

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.